Neoadjuvant chemo-immunotherapy transformed early-stage non-small cell lung cancer (NSCLC) treatment. However, the prognostic value of different pathological responses and the impact of adjuvant immunotherapy within a chemo-immunotherapy perioperative strategy remains unclear. We estimated time-to-event outcomes by graphical reconstruction of event-free survival (EFS) curves by pathological response (pCR, MPR, no-MPR) reported in early-stage NSCLC neoadjuvant/perioperative chemo-immunotherapy trials. MPR 1-10% subgroup, previously unreported, was retrieved by removing patients achieving pCR from the MPR group. Survival analysis by pathological response and comparison between neoadjuvant/perioperative strategies within subgroups were assessed. A statistically significant EFS difference according to pathological response was found, showing a prognostic gradient shifting from pCR (good), MPR 1-10% (intermediate) and no-MPR (poor). There was no difference between neoadjuvant/perioperative strategies within subgroups, however a trend for EFS benefit with perioperative and neoadjuvant chemo-immunotherapy was observed in MPR 1-10% and no-MPR patients, respectively. In conclusio, a pathological response-based algorithm could better tailor early-stage NSCLC treatment.
© The Author(s) 2025. Published by Oxford University Press. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.